Primary Recipient

ASKLEPIOS BIOPHARMACEUTICAL, INC

Amount

$2,999,988.00

Award Date

6/01/2010

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

This RC3 project award is designed to develop a hemophilia B nucleic-acid- (DNA-) based therapy capable of mediating multi-year expression of Factor IX (FIX) at therapeutic levels from a single administration that is anticipated to cost less than 2 years